• For investors assessing whether Tempus AI at around US$49.59 is starting to look like value or still pricing in a lot of optimism, this article breaks down what the current valuation reflects.
• The stock has been volatile, with the share price falling 5.1% over the past week, rising 5.6% over the last month, and remaining down 20.5% year to date and 30.4% over the past year.
• Recent news flow has focused on Tempus AI's position within life sciences and AI driven healthcare tools. Investors are weighing the promise of its technology against execution and funding risks. Commentary has also highlighted how sentiment around AI related healthcare stocks more broadly can spill over into individual names like Tempus AI, which helps explain some of the sharp moves in the share price.
• Tempus AI currently holds a valuation score of 3 out of 6, which means it screens as undervalued on half of Simply Wall St's checks. The next sections will walk through those methods and then outline a more holistic way to think about what the stock might be worth.

Approach 1: Tempus AI Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting those back to today’s value.

For Tempus AI, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow shows a loss of $225.6m. This means the starting point is clearly cash burning rather than cash generating.

Analysts provide free cash flow estimates out to 2030, with Simply Wall St extrapolating beyond the initial years. By 2030, Tempus AI’s free cash flow is projected at $443.3m. The ten year projection window extends this further using estimated growth rates after the analyst horizon.

When all those forecast cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about $88.95 per share. Compared with the recent share price of around $49.59, this implies the stock screens as 44.2% undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Tempus AI is undervalued by 44.2%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Tempus AI Price vs Sales

For companies that are still reporting losses or very small profits, the price to sales, or P/S, ratio is often more useful than P/E because it focuses on what the market is paying for each dollar of revenue rather than earnings that can be volatile or negative.

In general, investors tend to accept a higher P/S multiple when they expect stronger growth and see fewer risks. Slower expected growth and higher risk usually justify a lower, more conservative multiple. That context helps frame where Tempus AI trades today.

Tempus AI is currently on a P/S of 6.53x, which is above the Life Sciences industry average of 3.74x and also higher than the peer group average of 3.67x. Simply Wall St’s Fair Ratio framework, which estimates what a reasonable P/S might be after accounting for factors like earnings growth, profit margins, industry, market cap and specific risks, suggests a Fair Ratio of 7.13x for Tempus AI.

Because the Fair Ratio of 7.13x is above the current 6.53x, this approach points to the stock trading below the level implied by those fundamentals.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Tempus AI Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a simple story behind your numbers by linking your view of Tempus AI’s business, your revenue, earnings and margin assumptions, and your fair value estimate to the current share price. They update automatically as new news or earnings arrive and allow you to compare very different viewpoints, such as a more cautious fair value around US$35 that leans heavily on funding and reimbursement risks, versus a more optimistic fair value around US$105 that focuses on the scale of Tempus AI’s data platform and AI partnerships. All of this is available within an easy Community page tool used by millions of investors.

Do you think there's more to the story for Tempus AI? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.